Compare Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. with Similar Stocks
Stock DNA
Pharmaceuticals & Biotechnology
HKD 37,740 Million ()
1.00
NA
0.53%
-0.14
7.52%
0.84
Revenue and Profits:
Net Sales:
26,267 Million
(Quarterly Results - Mar 2026)
Net Profit:
2,058 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-6.11%
0%
-6.11%
6 Months
-15.39%
0%
-15.39%
1 Year
-12.25%
0%
-12.25%
2 Years
-24.26%
0%
-24.26%
3 Years
-32.64%
0%
-32.64%
4 Years
-23.89%
0%
-23.89%
5 Years
-31.32%
0%
-31.32%
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
3.00%
EBIT Growth (5y)
-2.08%
EBIT to Interest (avg)
8.76
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
1.57
Tax Ratio
17.61%
Dividend Payout Ratio
48.05%
Pledged Shares
0
Institutional Holding
0.14%
ROCE (avg)
14.64%
ROE (avg)
11.75%
Valuation key factors
Factor
Value
P/E Ratio
1
Industry P/E
Price to Book Value
0.07
EV to EBIT
4.35
EV to EBITDA
3.56
EV to Capital Employed
0.27
EV to Sales
0.18
PEG Ratio
0.08
Dividend Yield
6.45%
ROCE (Latest)
6.19%
ROE (Latest)
7.52%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bearish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Jun 2011
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.14%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
26,267.00
24,028.00
9.32%
Operating Profit (PBDIT) excl Other Income
2,435.20
2,474.40
-1.58%
Interest
116.70
108.60
7.46%
Exceptional Items
-3.90
-10.30
62.14%
Consolidate Net Profit
2,058.00
1,985.90
3.63%
Operating Profit Margin (Excl OI)
92.70%
92.30%
0.04%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 9.32% vs -3.75% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 3.63% vs -10.16% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
83,991.00
81,106.10
3.56%
Operating Profit (PBDIT) excl Other Income
4,400.70
4,645.10
-5.26%
Interest
463.10
476.40
-2.79%
Exceptional Items
-23.30
-377.60
93.83%
Consolidate Net Profit
3,319.40
3,253.50
2.03%
Operating Profit Margin (Excl OI)
40.10%
44.80%
-0.47%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 3.56% vs -2.36% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is 2.03% vs -30.87% in Dec 2024
About Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd. 
Guangzhou Baiyunshan Pharmaceutical Holdings Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






